Is there any potential management against COVID-19? A systematic review and meta-analysis.
Haleh Talaie,Sayed Masoud Hosseini,Maryam Nazari,Yadollah Fakhri,Atieh Mousavizadeh,Hossein Vatanpour,Ali Firoozfar +6 more
Reads0
Chats0
TLDR
All the included interventions significantly declined the mortality and enhanced clinical improvements with no effect on negative conversion and mechanical ventilation demand and especially, immunomodulators and plasma therapy showed favorable outcomes.Abstract:
A recent survey has shown that the COVID-19 pandemic has culminated in dramatical and critical treatment particularly in acute infected patients. In fact, this systematic review-meta-analysis was directly pertained to estimation at the efficient value of some clinical managements to confront the COVID-19 infection. Pubmed, Embase, Scopus, Cochrane, and Scholar databases were searched from inception to July 1, 2020, to identify studies reporting the current treatment process and medications (e.g. hydroxychloroquine, antiviral therapy, convalescent plasma, and immunomodulatory agents) for COVID-19. A random-effects model meta-analysis was performed to calculate the relative risk (RR) with 95% confidence intervals (CI). The outcomes of this study were the frequency of negative conversion cases, clinical improvements, mechanical ventilation demand, intensive care unit (ICU) entry, and mortality. The standard treatment refers to the published guidelines and specialist experience which varies in different articles, and the proposed treatment refers to the kind of interest suggested in the included studies. A number of 45 articles met the eligibility criteria (out of 6793 articles). Among them, 26 articles involving 3263 patients were included in quantitative analysis. Anti-COVID-19 interventions could significantly increase clinical improvement (RR 1.17, 95% CI 1.08–1.27; I2 = 49.8%) and reduce the mortality rate (RR 0.58, 95% CI 0.35–0.95; I2 = 74.8%). Although in terms of negative conversion, ICU entry, and mechanical ventilation demand, clinical intervention had no beneficial effect. The clinical effect of immunomodulatory agents (especially tocilizumab and anakinra) was noticeable compared to other medications with RR of 0.22 (95% CI 0.09–0.53; I2 = 40.9%) for mortality and 1.25 (95% CI 1.07–1.46; I2 = 45.4%) for clinical improvement. Moreover, Antivirals (RR 1.13, 95% CI 1.01–1.26; I2 = 47.0%) and convalescent plasma therapy (RR 1.41, 95% CI 1.01–1.98; I2 = 66.6%) had significant beneficial effects on clinical improvement. Based on our findings, all the included interventions significantly declined the mortality and enhanced clinical improvements with no effect on negative conversion and mechanical ventilation demand. Especially, immunomodulators and plasma therapy showed favorable outcomes.read more
Citations
More filters
Remdesivir as a possible therapeutic option for the COVID-19
TL;DR: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.
Journal ArticleDOI
Interleukin-1 blocking agents for treating COVID-19.
Mauricia Davidson,Sonia Menon,Anna Chaimani,Theodoros Evrenoglou,Lina Ghosn,Carolina Graña,Nicholas Henschke,Elise Cogo,Gemma Villanueva,Gabriel Ferrand,Carolina Riveros,H. Bonnet,Philipp Kapp,Conor Moran,Declan Devane,Joerg J Meerpohl,Gabriel Zada,Asbjørn Hróbjartsson,Giacomo Grasselli,David Tovey,Philippe Ravaud,Isabelle Boutron +21 more
TL;DR: The effects of IL-1 blocking agents compared with standard care alone or with placebo on effectiveness and safety outcomes in people with COVID-19 are assessed and the certainty of evidence is rated using the GRADE approach for the critical outcomes of clinical improvement.
Journal ArticleDOI
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.
Cathrine Axfors,Cathrine Axfors,Perrine Janiaud,Andreas M. Schmitt,Andreas M. Schmitt,Janneke van 't Hooft,Emily R. Smith,Noah Haber,Akin Abayomi,Manal Abduljalil,Abdulkarim Abdulrahman,Yeny Acosta-Ampudia,Manuela Aguilar-Guisado,Farah Al-Beidh,Marissa M. Alejandria,Rachelle N. Alfonso,Mohammed K. Ali,Manaf AlQahtani,Alaa AlZamrooni,Juan-Manuel Anaya,Mark Angelo C. Ang,Ismael F. Aomar,Luis E. Argumanis,Alexander Averyanov,Vladimir P. Baklaushev,Olga Balionis,Thomas Benfield,Scott Berry,Nadia Birocco,Lynn B. Bonifacio,Asha C. Bowen,Asha C. Bowen,Abbie Bown,Carlos Cabello-Gutierrez,Bernardo Camacho,Adrián Camacho-Ortiz,Sally Campbell-Lee,Damon H. Cao,Ana Cardesa,Jose M. Carnate,German Jr J. Castillo,Rossana Cavallo,Fazle Rabbi Chowdhury,Forhad Hossain Chowdhury,Giovannino Ciccone,Antonella Cingolani,Fresthel Monica M. Climacosa,Veerle Compernolle,Carlo Francisco N. Cortez,Abel Costa Neto,Sergio D’Antico,James Daly,Franca Danielle,Joshua S. Davis,Francesco Giuseppe De Rosa,Justin T Denholm,Justin T Denholm,Claudia M. Denkinger,Daniel Desmecht,Juan C. Díaz-Coronado,Juan A. Díaz Ponce-Medrano,Anne Françoise Donneau,Teresita E. Dumagay,Susanna Dunachie,Cecile C. Dungog,Olufemi Erinoso,Ivy Mae S. Escasa,Lise J Estcourt,Lise J Estcourt,Amy Evans,Agnes L.M. Evasan,Christian J. Fareli,Veronica Fernandez-Sanchez,Claudia Galassi,Juan E. Gallo,Patricia J. Garcia,Patricia L. Garcia,Jesus A. Garcia,Mutien Garigliany,Elvira Garza-González,Deonne Thaddeus V. Gauiran,Paula A. Gaviria García,Jose Antonio Giron-Gonzalez,David Gómez-Almaguer,Anthony C. Gordon,Anthony C. Gordon,André Gothot,Jeser Santiago Grass Guaqueta,Cameron Green,David Grimaldi,Naomi E Hammond,Heli Harvala,Francisco M. Heralde,Jesica A. Herrick,Alisa Higgins,Thomas Hills,Thomas Hills,Jennifer Hines,Karin Holm,Ashraful Hoque,Eric Hoste,Jose M. Ignacio,Alexander V. Ivanov,Maike Janssen,Jeffrey H. Jennings,Vivekanand Jha,Vivekanand Jha,Vivekanand Jha,Ruby Anne N King,Jens Kjeldsen-Kragh,Paul Klenerman,Aditya Kotecha,Fiorella Krapp,Luciana Labanca,Emma Laing,Mona Landin-Olsson,Pierre-François Laterre,Lyn Li Lim,Jodor Lim,Oskar Ljungquist,Jorge M. Llaca-Díaz,Concepción López-Robles,Salvador López-Cárdenas,Ileana Lopez-Plaza,Josephine Anne C. Lucero,Maria Lundgren,Juan Macías,Sandy C. Maganito,Anna Flor G. Malundo,Rubén D. Manrique,Paola M. Manzini,Miguel Marcos,Ignacio Marquez,Francisco Javier Martínez-Marcos,Ana M. Mata,Colin McArthur,Zoe McQuilten,Bryan J. McVerry,David K. Menon,Geert Meyfroidt,Ma Angelina L. Mirasol,Benoît Misset,James S. Molton,Alric V. Mondragon,Diana M. Monsalve,Parastoo Moradi Choghakabodi,Susan C. Morpeth,Paul R. Mouncey,Michel Moutschen,Carsten Müller-Tidow,Erin Murphy,Tome Najdovski,Alistair Nichol,Alistair Nichol,Henrik Nielsen,Richard M. Novak,Matthew V. N. O'Sullivan,Matthew V. N. O'Sullivan,Matthew V. N. O'Sullivan,Julián Olalla,Akin Osibogun,Bodunrin Osikomaiya,Salvador Oyonarte,Juan Mauricio Pardo-Oviedo,Mahesh C. Patel,David L. Paterson,Carlos A. Peña-Perez,Ángel Augusto Pérez-Calatayud,Eduardo Perez-Alba,Anastasia Perkina,Naomi Perry,Mandana Pouladzadeh,Inmaculada Poyato,David Price,Anne Kristine H. Quero,M. Rahman,S. Rahman,Mayur Ramesh,Carolina Ramírez-Santana,Magnus Rasmussen,Megan Rees,Megan Rees,Eduardo Rego,Jason A. Roberts,Jason A. Roberts,Jason A. Roberts,David J. Roberts,David J. Roberts,Yhojan Rodríguez,Jesús Rodríguez-Baño,Benjamin A. Rogers,Manuel Rojas,Alberto Romero,Kathryn M Rowan,Fabio Saccona,Mehdi Safdarian,Maria Clariza M. Santos,Joe Sasadeusz,Joe Sasadeusz,Gitana Scozzari,Manu Shankar-Hari,Manu Shankar-Hari,Gorav Sharma,Tom Snelling,Alonso Soto,Pedrito Y. Tagayuna,Amy Tang,Geneva Tatem,Luciana Teofili,Steven Y. C. Tong,Steven Y. C. Tong,Alexis F. Turgeon,Januario D. Veloso,Balasubramanian Venkatesh,Balasubramanian Venkatesh,Balasubramanian Venkatesh,Yanet Ventura-Enriquez,Steve Webb,Steve Webb,Lothar Wiese,Christian Wikén,Erica M. Wood,Gaukhar M. Yusubalieva,Kai Zacharowski,Ryan Zarychanski,Nina Khanna,David Moher,Steven N. Goodman,John P. A. Ioannidis,Lars G. Hemkens,Lars G. Hemkens +230 more
TL;DR: In this article, the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials, were evaluated.
Journal ArticleDOI
Interleukin-1 blocking agents for treating COVID-19
TL;DR: In this paper , the effects of IL-1 blocking agents compared with standard care alone or with placebo on effectiveness and safety outcomes in people with severe coronavirus disease 2019 (COVID-19) were assessed.
Journal ArticleDOI
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro , in vivo , and clinical trials.
Young Joo Han,Keum Hwa Lee,Sojung Yoon,Seoung Wan Nam,Seohyun Ryu,Dawon Seong,Jaeseok Kim,Jun Young Lee,Jae Won Yang,Jinhee Lee,Ai Koyanagi,Sung Hwi Hong,Elena Dragioti,Joaquim Radua,Lee Smith,Hans Oh,Ramy Abou Ghayda,Andreas Kronbichler,Maria Effenberger,Daniela Kresse,Sara Denicolò,Woosun Kang,Louis Jacob,Hanwul Shin,Jae Il Shin +24 more
TL;DR: There was no therapeutic agent that consistently resulted in positive outcomes across SARS, MERS, and COVID-19 and further RCTs are required.
References
More filters
Journal ArticleDOI
Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.
Brandon Michael Henry,Maria Helena Santos de Oliveira,Stefanie W. Benoit,Stefanie W. Benoit,Mario Plebani,Giuseppe Lippi +5 more
TL;DR: Several biomarkers which may potentially aid in risk stratification models for predicting severe and fatal COVID-19 were identified and clinicians are advised to closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness.
Journal ArticleDOI
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Ivan Hung,Kwok Cheung Lung,Eugene Yuk Keung Tso,Raymond W. Liu,Tom Wai-Hin Chung,Man Yee Chu,Yuk Yung Ng,Jenny Lo,Jacky Chan,Anthony Raymond Tam,Hoi-Ping Shum,Veronica L. Chan,Alan Ka Lun Wu,Kit Man Sin,Wai Shing Leung,Wai Lam Law,David Christopher Lung,Simon Yung Wa Sin,Pauline Yeung,Cyril C. Y. Yip,Ricky Ruiqi Zhang,Agnes Yim Fong Fung,Erica Yuen Wing Yan,Kit-Hang Leung,Jonathan Daniel Ip,Allen Wing-Ho Chu,Wan Mui Chan,Anthony Chin-Ki Ng,Rodney A. Lee,Kitty S. C. Fung,Alwin Wt Yeung,Tak Chiu Wu,Johnny W.M. Chan,Wing Wah Yan,Wai-Ming Chan,Jasper Fuk-Woo Chan,Albert K. W. Lie,Owen Tak Yin Tsang,Vincent C.C. Cheng,Tak-Lun Que,Chak Sing Lau,Kwok-Hung Chan,Kelvin K. W. To,Kwok-Yung Yuen +43 more
TL;DR: Yu et al. as mentioned in this paper assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19.
Journal ArticleDOI
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
Ling Li,Zhang Wei,Yu Hu,Xunliang Tong,Shangen Zheng,Juntao Yang,Yujie Kong,Lili Ren,Qing Wei,Heng Mei,Caiying Hu,Cuihua Tao,Ru Yang,Jue Wang,Yongpei Yu,Guo Yong,Xiaoxiong Wu,Zhihua Xu,Li Zeng,Nian Xiong,Lifeng Chen,Juan Wang,Ning Man,Yu Liu,Haixia Xu,E. Deng,Xuejun Zhang,Chenyue Li,Conghui Wang,Shisheng Su,Linqi Zhang,Jianwei Wang,Yanyun Wu,Zhong Liu +33 more
TL;DR: Among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days.
Journal ArticleDOI
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Jason D Goldman,David C. Lye,David S.C. Hui,Kristen M. Marks,Raffaele Bruno,Rocio Montejano,Christoph D. Spinner,Massimo Galli,Mi Young Ahn,Ronald Nahass,Yao Shen Chen,Devi SenGupta,Robert H. Hyland,Anu Osinusi,Huyen Cao,Christiana Blair,Xuelian Wei,Anuj Gaggar,Diana M. Brainard,William J. Towner,Jose Muñoz,Kathleen M. Mullane,Francisco M. Marty,Karen T. Tashima,George A. Diaz,Aruna Subramanian +25 more
TL;DR: In patients with severe Covid-19 not requiring mechanical ventilation, a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia, the magnitude of benefit cannot be determined.
Journal ArticleDOI
Tocilizumab treatment in COVID-19: A single center experience.
TL;DR: TCZ appears to be an effective treatment option in COVID‐19 patients with a risk of cytokine storms and for these critically ill patients with elevated IL‐6, the repeated dose of the TCZ is recommended.